PDCD1 and neoplasm: The tumor weights of the olaparib single-drug group and anti-PD1 single-drug group were both lighter than those of the control group, while the combination group of olaparib and anti-PD1 showed more excellent tumor volume reduction effect, consistent with tumor growth volume results(Figure 8(b)).